Abstract
This document serves as a formal corrigendum for the research paper "A modifier screen identifies DNAJB6 as a cardiomyopathy susceptibility gene," originally published in JCI Insight in 2016. The original study identified DNAJB6 as a critical modifier gene influencing the development and severity of various forms of cardiomyopathy. This specific amendment corrects a typographical error in Table 2 regarding the nucleotide notation for the p.F93F variant. Accurate genetic mapping is essential for the clinical interpretation of variants associated with Dilated Cardiomyopathy (DCM) and Hypertrophic Cardiomyopathy (HCM).
Introduction
Cardiomyopathy is a complex condition characterized by structural and functional abnormalities of the heart muscle. While many primary causative genes have been identified, the clinical variability observed in patients often suggests the influence of "modifier genes." These genes do not cause the disease independently but can significantly alter the phenotypic expression of other mutations.
The original study identified DNAJB6, a member of the Hsp40 (Heat Shock Protein 40) chaperone family, as a significant susceptibility gene. Chaperone proteins like DNAJB6 are vital for maintaining protein homeostasis within cardiac cells, preventing the misfolding and aggregation of proteins that can lead to heart failure. This corrigendum ensures that the genetic data supporting these findings is accurately recorded, specifically addressing the notation of variants that may impact clinical diagnostics.
Methods and Data Sources
The researchers employed a multi-faceted approach to identify and validate DNAJB6 as a modifier gene:
- Modifier Screening: A systematic screen was conducted to find genes that modulate the severity of cardiomyopathy phenotypes.
- Patient Cohort Sequencing: A cohort of 325 individuals diagnosed with various forms of cardiomyopathy was screened for mutations within the DNAJB6 gene.
- Bioinformatic Prediction: Tools such as SIFT (Sorting Intolerant From Tolerant) and PolyPhen2 (Polymorphism Phenotyping v2) were used to estimate the functional impact of identified amino acid substitutions.
- Population Frequency Analysis: To determine the rarity of the variants, their prevalence was compared against large-scale genomic databases, including the Exome Variant Server (EVS) and the Exome Aggregation Consortium (ExAC).
Corrected Results and Key Insights
The primary correction involves the p.F93F variant. In the original publication, the nucleotide change was misreported. The corrected entry is c.279 C>T (p.F93F). This variant is particularly noteworthy because, although it is a synonymous mutation (the amino acid Phenylalanine remains unchanged), it is identified as a cryptic splice-site variant. Such mutations can disrupt the normal splicing of pre-mRNA, potentially leading to the production of non-functional proteins.
The corrected Table 2 provides a comprehensive overview of the DNAJB6 variants identified in the study:
- c.886G > A / c.887C > G (p.A296R): This complex variant was found in a patient with atypical DCM, HCM, and congenital heart block. It was predicted as "Damaging" by SIFT, highlighting its likely pathogenic role.
- c.947C > G (p.S316W): Identified in DCM patients, this variant was predicted as "Possibly damaging" by PolyPhen2.
- c.573A > G (p.I191M): Found in DCM patients but predicted as "Tolerated" or "Benign" by bioinformatic tools, suggesting a potentially less severe impact.
- c.962C > T (p.S321L): Associated with HCM and predicted as "Damaging" by SIFT.
- c.279 C>T (p.F93F): The corrected variant, found in HCM patients. It has a Minor Allele Frequency (MAF) of 0.14% in the general population, which is relatively higher than the other variants but still rare enough to be considered a potential modifier.
Discussion and Clinical Significance
The identification of DNAJB6 variants across a spectrum of heart diseases—including Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM), and Left Ventricular Noncompaction (LVNC)—illustrates the gene's broad influence on cardiac health. The correction of the p.F93F notation is critical for clinical geneticists who rely on precise nucleotide data to assess the pathogenicity of variants found in patients.
Synonymous mutations like c.279 C>T are often overlooked in initial screenings, yet they can have profound effects on protein function through non-canonical mechanisms like splicing interference. This corrigendum reinforces the need for meticulous data reporting and the consideration of "silent" mutations in the genetic architecture of complex diseases like cardiomyopathy. Future research will continue to explore the functional consequences of these DNAJB6 variants through in vitro and in vivo models to further elucidate their role in heart failure.
Summary updated